Myriad Genetics Shares Fall Despite Partnership With Jscreen
Myriad Genetics and Jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible With Electronic Medical Record Integration
Myriad Genetics (NASDAQ:MYGN) Shareholders Are Still up 61% Over 1 Year Despite Pulling Back 7.9% in the Past Week
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $32
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $34
Stephens Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Myriad Genetics(MYGN.US), With a Forecast Between $32 to $40
Scotiabank Keeps Their Buy Rating on Myriad Genetics (MYGN)
Steady Growth and Market Stability Justify Hold Rating for Myriad Genetics
Myriad Genetics: A Buy Rating Amid Reaffirmed Strategy and Growth Potential
J.P. Morgan Maintains Myriad Genetics(MYGN.US) With Sell Rating, Maintains Target Price $20
Myriad Genetics: Assessing Sustainability of Revenue Growth Amid Market Challenges
BofA Securities Initiates Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $18
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Alnylam Pharma (ALNY)
Myriad Genetics Expects Q3 Revenue Slightly Above Wall Street Estimates
Express News | Myriad Genetics Inc: Reaffirms Full-Year 2024 Revenue Guidance of $835M-$845M
Express News | Myriad Genetics: Expects Q3 Revenue About $210 Mln-$212 Mln
Myriad Genetics Outlines Five Projects on Studying Breast Cancer Test
Express News | Myriad Genetics Announces Five Research Collaborations to Study the Use of Mrd Testing in Breast Cancer